EFFICIENCY OF ADDING AN IMMUNE RESTORATIVE AGENT TO THE CURRENT TREATMENT REGIMENS OF PULMONARYTUBERCULOSIS PATIENTS WITH DRUG RESISTANCE

Abstract

The single prospective study was conducted in order to assess clinical efficiency of adding the immune restorative agent of deoxyribonucleat sodium (Derinat) to the current chemotherapy regimens of 102 patients (new cases or relapses) with destructive pulmonary tuberculosis with multiple or extensive drug resistance; the patients were divided into two groups: the main group included 30 patients who were prescribed with intramuscular injections of Derinat, 5 ml, every 24 hours with 48 hours interval, 10 injections in total; and nebulizer inhalations with mixture of Derinat and saline solution in the proportion of 1:1 (2 ml of Derinat and 2 ml of saline solution), once a day, 20 inhalations in total; the comparison group included 72 patients, who had no Derinat prescribed. When compared to the control group, the group of patients treated with the immunomodulator had a shorter period of clinical manifestations elimination, increase in the frequency of sputum conversion (by 28.6% by the 4th month of treatment), reduction in the rate of eradication of bronchial tree mucus inflammations, increase in the frequency of cavity healing (by 20% by the 6th month of treatment).